7/9
09:00 am
ntra
Natera (NTRA) had its "overweight" rating reaffirmed by Morgan Stanley.
Medium
Report
Natera (NTRA) had its "overweight" rating reaffirmed by Morgan Stanley.
7/9
06:00 am
ntra
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
Low
Report
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
7/6
10:00 am
ntra
Natera (NTRA) had its "outperform" rating reaffirmed by Evercore Inc.
Low
Report
Natera (NTRA) had its "outperform" rating reaffirmed by Evercore Inc.
7/6
06:00 am
ntra
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Low
Report
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
6/29
09:00 am
ntra
Natera (NTRA) had its "buy" rating reaffirmed by Guggenheim.
Medium
Report
Natera (NTRA) had its "buy" rating reaffirmed by Guggenheim.
6/29
06:46 am
ntra
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer [Yahoo! Finance]
Medium
Report
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer [Yahoo! Finance]
6/29
06:00 am
ntra
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Medium
Report
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
6/27
05:33 am
ntra
Natera (NTRA) was upgraded by Sanford C. Bernstein to "strong-buy".
Medium
Report
Natera (NTRA) was upgraded by Sanford C. Bernstein to "strong-buy".
6/26
04:06 pm
ntra
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise [Seeking Alpha]
Medium
Report
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise [Seeking Alpha]
6/26
09:32 am
ntra
Natera (NTRA) had its "outperform" rating reaffirmed by Sanford C. Bernstein. They now have a $310.00 price target on the stock.
Low
Report
Natera (NTRA) had its "outperform" rating reaffirmed by Sanford C. Bernstein. They now have a $310.00 price target on the stock.
6/25
07:21 am
ntra
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial [Yahoo! Finance]
Low
Report
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial [Yahoo! Finance]
6/25
07:00 am
ntra
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Low
Report
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
6/24
04:00 pm
ntra
Natera (NTRA) was given a new $275.00 price target by BTIG Research.
Low
Report
Natera (NTRA) was given a new $275.00 price target by BTIG Research.
6/24
10:55 am
ntra
Natera (NTRA) had its price target lowered by Barclays PLC from $280.00 to $260.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NTRA) had its price target lowered by Barclays PLC from $280.00 to $260.00. They now have an "overweight" rating on the stock.
6/24
07:00 am
ntra
Natera (NTRA) was given a new $260.00 price target by UBS Group AG.
High
Report
Natera (NTRA) was given a new $260.00 price target by UBS Group AG.
6/24
05:00 am
ntra
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
High
Report
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
6/24
03:00 am
ntra
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
Medium
Report
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
6/23
04:17 pm
ntra
Natera (NTRA) had its price target raised by BTIG Research from $250.00 to $270.00. They now have a "buy" rating on the stock.
High
Report
Natera (NTRA) had its price target raised by BTIG Research from $250.00 to $270.00. They now have a "buy" rating on the stock.
6/23
06:00 am
ntra
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
Medium
Report
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
6/19
03:30 pm
ntra
Pirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA Monitoring [Yahoo! Finance]
Low
Report
Pirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA Monitoring [Yahoo! Finance]
6/18
06:00 am
ntra
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
Low
Report
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
6/17
09:56 am
ntra
Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials [Yahoo! Finance]
Low
Report
Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials [Yahoo! Finance]
6/13
10:40 am
ntra
Forget SpaceX Hype: Billionaire Stanley Druckenmiller is Loading Up on This Unknown Healthcare Stock [Yahoo! Finance Canada]
Low
Report
Forget SpaceX Hype: Billionaire Stanley Druckenmiller is Loading Up on This Unknown Healthcare Stock [Yahoo! Finance Canada]
6/13
09:57 am
ntra
Forget SpaceX Hype: Billionaire Stanley Druckenmiller is Loading Up on This Unknown Healthcare Stock [Yahoo! Finance]
Low
Report
Forget SpaceX Hype: Billionaire Stanley Druckenmiller is Loading Up on This Unknown Healthcare Stock [Yahoo! Finance]
6/11
06:00 pm
ntra
Natera (NTRA) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.
Low
Report
Natera (NTRA) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.